Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- NTNX -14.7%, NKE -9.4%, SCHL -1.3% (also authorizes new $150 mln share repurchase program)
Other news:
-
NVA -16.3% ( announces pricing of public offering)
-
SAVA -14.4% (no longer expects to initiate a proof-of-concept clinical trial for simufilam in TSC-related epilepsy in the first half of 2026 as previously disclosed )
-
CGTX -2.7% ( also entered into an Open Market Sale Agreement )
-
ALT -2.6% (announces that pemvidutide achieved key measures of success at 48 weeks in IMPACT Phase 2b MASH Trial; Conference call to be held today at 8:00 a.m. ET)
-
GLPG -2.3% (topline results from two Phase 3 enabling studies),
-
ENVA -1.4% (and Grasshopper amended merger)
-
CGTX -1.3% (files for $300 mln mixed shelf offering; also enters sales agreement up to $75 mln of stock),
- BANX -1.3% (announces $14.9 million registered direct offering )